Drugs / Allogeneic Mesenchymal Stromal Cells (MSC)
Allogeneic Mesenchymal Stromal Cells (MSC)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07431645 | Apr 2023 → Oct 2025 | head and neck cancer, radiation-induced disorder | Institute of Oncology Ljubljana | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Mesenchymal Stromal Cells (MSC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07431645 ↗ |
| Modality | Cell therapy | “allogeneic mesenchymal stromal stem cells (MSCs)” NCT07431645 ↗ |